This article was originally published by Targeted Oncology As part of a virtual Case Based Peer Perspective event, Jesus G. Berdeja, MC, director of Myeloma Research, Sarah Cannon Research Institute, in Nashville, Tennesee, discussed the treatment options for stage II multilple myeloma, based on a case of a 71-year female patient. Targeted Oncology™: Is this...Continue Reading

This article was originally published by AJMC MRD Should Be More Widely Used in Clinical Care of MM, Report Argues Advances in scientists’ understanding of multiple myeloma (MM) and in the ability to assess minimal residual disease (MRD) have made the metric an important method to track the efficacy of therapy in clinical trial settings....Continue Reading

This article was originally published by Cancer Health New drugs to treat multiple myeloma are producing better results for patients, with fewer side effects. For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested...Continue Reading

This article was originally published by Targeted Oncology. C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of chimeric antigen receptor (CAR) T cells and CAR natural killer (NK) cells in the multiple myeloma setting. As with every therapy, there are pros and cons...Continue Reading

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies. The Food and Drug Administration has granted accelerated approval to a drug for multiple myeloma that is the first of...Continue Reading

For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results...Continue Reading

This article was originally published by Cancer Therapy Advisor Researchers have used deep whole-genome sequencing (WGS) to identify genomic markers of a “good-risk” group of patients with multiple myeloma with prolonged survival. Specifically, patients found to have a low genomic scar score and chromosome 9 gain had superior outcomes. In the study, researchers analyzed WGS...Continue Reading

This was originally published by AJMC Severe renal impairment (RI) is associated with decreased rates of survival among patients with multiple myeloma (MM), even if renal function is restored with therapy, according to new research. Investigators from Fujian Medical University Union Hospital in China found patients who achieved restoration of renal function recovery had somewhat better odds...Continue Reading

This article was originally published by Cancer Therapy Advisor Receipt of dialysis may be a risk factor for inpatient mortality in patients with multiple myeloma (MM) being treated with high-dose melphalan and autologous stem cell transplantation (HDM-ASCT), according to study results published in the European Journal of Haematology. To evaluate inpatient mortality trends, investigators conducted a...Continue Reading

This post was originally published by Myasthenia Gravis News A 60-year-old man being treated for multiple myeloma was found to have myasthenia gravis (MG) caused by antibodies against muscle-specific tyrosine kinase (MuSK), a study reports. This unusual case indicates that cancer treatments may mask the symptoms of MG, complicating diagnosis, researchers said. The case was described in the journal BMC Neurology,...Continue Reading